The FDA Modernization Act of 1997 established the Fast Track designation to expedite developing and reviewing new drugs ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Olema has successfully completed IND-enabling studies in support of a potential Investigational New Drug (IND) application with the FDA and expects to initiate Phase 1 clinical trials for OP-3136 in ...

The U.S. Food and Drug Administration (FDA) has cleared Northwestern University’s Investigational New Drug (IND) application for Calidi’s NeuroNova (CLD-101). CLD-101 is a novel stem-cell based ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025.

Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company ...

The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...